All
Biologics' efficacy data growing
September 1st 2005Chicago — Among the more promising directions among biologic drugs for psoriasis are longer treatment regimens and combinations with other modalities, says Mark Lebwohl, M.D., professor and chairman, department of dermatology, Mount Sinai School of Medicine, New York.
Offer systemic therapy as first-line defense
September 1st 2005Buenos Aires — In selecting therapies for patients with psoriasis, dermatologists need to consider that psoriasis is a life-long, systemic disease that substantially affects a patient's quality of life, according to Alan Menter, M.D., chief of the division of dermatology at Baylor University Medical Center, Dallas.
Pharma industry prescribes record dosage of lobbying funds
August 2nd 2005The pharmaceutical industry last year spent a record $128 million on lobbying efforts -- more than any other business sector, according to a report released last month by the Center for Public Integrity, a non-profit public-policy research group.
Cancer 'grid' allows sharing of information
August 1st 2005Anaheim, Calif. — The cancer Biomedical Informatics Grid, or caBIG, is an important introduction of information technology to the war on cancer, much the same as information technology has been used to transform business and the military, according to Kenneth H. Buetow, Ph.D., director of the NCI Center for Bioinformatics and laboratory chief, Laboratory of Population Genetics, National Cancer Institute, Bethesda, Md.
Systemic sunscreen still in future, despite promise of antioxidants
August 1st 2005Vienna, Austria — Although there appears to be potential for developing systemic methods of protecting skin from sun damage, researchers still seem to be a long way from determining how to do that, according to Harald Maier, M.D.
Tumor, oxygen link provides clues for new cancer therapies
August 1st 2005Philadelphia — The unraveling of the relationship between tumor growth and falling oxygen levels is expanding what is known about cancer and encouraging research into new antitumor therapies, according to M. Celeste Simon, Ph.D.
Today's fillers: Carefully consider product choices for patients to achieve 'customized' outcomes
August 1st 2005The broad range of fillers available today allows dermatologists to target any depth of the skin and treat an array of cosmetic defects. Now, according to Kevin Pinski, M.D., the emphasis is on indications, and analyzing the skin of each patient to determine which fillers would be best and then tailoring a treatment plan that's just right for that person.
Pseudolymphoma presents as leonine facies
August 1st 2005Newport Beach, Calif. — A rare instance of cutaneous pseudolymphoma presenting as leonine facies was recently diagnosed in Southern California and treated successfully with a prolonged prednisone taper, says Rebecca Scudiero, M.D., a resident in the division of dermatology, David Geffen School of Medicine, UCLA.